"Licensed" to cross-prime
Nature Immunology
March 1, 2010
NKT cells play an important role in cross priming ― a process whereby infectious agents outside the cell are taken up, processed, and presented to a certain type of T cell in order to create an immune response which is effective against tumours. The work, published online in Nature Immunology this week, suggests that NKT cells could potentially be an important new player in vaccine design.
Cross-priming critically depends on three cell types coming together: dendritic cells, a licensing cell, and a cytotoxic T cell (CTL). Normally, dendritic cells cross-prime infectious agents via the intervention of T helper cells ― which are licensing cells. However Christian Kurts and colleagues have revealed a novel mechanism where this process is instead triggered by another cell type entirely ― the NKT cell. Following interaction with NKT cells, dendritic cells secrete a chemical signal, which specifically attracts certain CTLs to them, where they can then be activated.
Until now it has been puzzling how the three rare cell types needed in order for cross-priming to occur can all interact in time and space. The NKT-elicited release of a chemical signal from dendritic cells provides a neat solution to this puzzle. The importance of NKT cells revealed by this study suggests that any future vaccine may be more effective if these cells are factored into their design.
doi: 10.1038/ni.1848
Research highlights
-
Jun 30
Genomics: Gray wolf genome hints at dual ancestry of dogsNature
-
Jun 30
Evolution: Hawks learn on the fly to swoop up before perchingNature
-
Jun 30
Microbiology: Transmission of gastrointestinal viruses in salivaNature
-
Jun 29
COVID-19: Assessing instances of long COVID in UK health dataNature Communications
-
Jun 24
Palaeontology: It sucked to be the prey of ancient cephalopodsScientific Reports
-
Jun 24
Sport science: New wearable sensor to measure neck strain may detect potential concussionScientific Reports